Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Human HTm4 is a hematopoietic cell cycle regulator
José L. Donato, … , Mohamed H. Sayegh, Chaker N. Adra
José L. Donato, … , Mohamed H. Sayegh, Chaker N. Adra
Published January 1, 2002
Citation Information: J Clin Invest. 2002;109(1):51-58. https://doi.org/10.1172/JCI14025.
View: Text | PDF
Article

Human HTm4 is a hematopoietic cell cycle regulator

  • Text
  • PDF
Abstract

Proper control of cell cycle progression is critical for the constant self-renewal, differentiation, and homeostasis of the hematopoietic system. Cells of all types share the common cell cycle regulators. The different expression patterns of common regulators, in a broad sense, define cell-type or lineage specificity. However, there remains the possibility of hematopoietic cell cycle regulators tailored to the demands of the hematopoietic system. Here we describe a novel protein, HTm4, which serves as a hematopoietic cell cycle regulator. Our data indicate that HTm4 is expressed in hematopoietic tissues and is tightly regulated during the differentiation of hematopoietic stem cells. It binds to cyclin-dependent kinase–associated (CDK-associated) phosphatase-CDK2 (KAP-CDK2) complexes, and the three proteins demonstrate similar patterns of cellular expression in human lymphoid tissues. HTm4 stimulates the phosphatase activity of KAP, and its C-terminal region is required for binding to KAP-CDK2 complexes and the modulation of KAP activity. Overexpression of HTm4 can cause cell cycle arrest at the G0/G1 phase. Thus, HTm4 is a novel hematopoietic modulator for the G1-S cell cycle transition.

Authors

José L. Donato, Jon Ko, Jeffery L. Kutok, Tao Cheng, Taro Shirakawa, Xiao-Quan Mao, David Beach, David T. Scadden, Mohamed H. Sayegh, Chaker N. Adra

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
The expression of HTm4 is highly regulated during the differentiation of...
The expression of HTm4 is highly regulated during the differentiation of hematopoietic stem cells. (a) MicroRT-PCR analysis of HTm4 expression in single hematopoietic cells at various stages of differentiation. Cell surface markers for each sample are denoted on the top row. G0 represents the quiescent CD34+/CD38– HSC. The middle row is a Southern blot analysis of HTm4 cDNA obtained through RT-PCR technique. The bottom row shows the loaded cDNA stained with ethidium bromide dye. Each lane represents a single cell. (b) Northern blot analysis of HTm4 expression in CD34+ cells that were induced to differentiate with the treatment of either G-CSF or Epo for time intervals as indicated. At day 11, cell populations are determined to be 60% neutrophils and 70% erythrocytes when induced with G-CSF and Epo, respectively.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts